Abstract
The ability of L-dopa to arrest pain can be used to predict objective response of skeletal disease to endocrine ablation or additive therapy. In the present study, 43 patients with painful skeletal metastases were evaluated for the relief of pain by L-dopa, given 250 mg to 500 mg orally every 4 hours for 4 days. Sixteen of the 25 responders to L-dopa had objective response to either previous or later hormonal therapy while all the 18 non-responders did not benefit from endocrine ablation. The results of L-dopa responses also correlated well to the presence of absence of cytoplasmic ER in tumor. These results demonstrate that both tests (L-dopa and ER) are reliable indicators, one complimenting the other, in prognosticating response to endocrine therapy and should be used prior to hormone treatment. Alternative therapy should be considered for patients who are non-responders to the L-dopa test and/or whose tumors contain negligible ER. The long term therapeutic value of L-Dopa, however, is limited.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dao T. L. Ablation therapy for hormone-dependent tumors. Annu Rev Med. 1972;23:1–18. doi: 10.1146/annurev.me.23.020172.000245. [DOI] [PubMed] [Google Scholar]
- Donoso A. O., Bishop W., Fawcett C. P., Krulich L., McCann S. M. Effects of drugs that modify brain monoamine concentrations on plasma gonadotropin and prolactin levels in the rat. Endocrinology. 1971 Sep;89(3):774–784. doi: 10.1210/endo-89-3-774. [DOI] [PubMed] [Google Scholar]
- Engelsman E., Heuson J. C., Blonk Van Der Wijst J., Drochmans A., Maass H., Cheix F., Sobrinho L. G., Nowakowski H. Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study. Br Med J. 1975 Jun 28;2(5973):714–715. doi: 10.1136/bmj.2.5973.714. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jensen E. V., Block G. E., Smith S., Kyser K., DeSombre E. R. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr. 1971 Dec;34:55–70. [PubMed] [Google Scholar]
- LIPSETT M. B., BERGENSTAL D. M. Lack of effect of human growth hormone and ovine prolactin on cancer in man. Cancer Res. 1960 Sep;20:1172–1178. [PubMed] [Google Scholar]
- Leung B. S., Krippaehne W. W., Fletcher W. S. Prognostic value of estrogen receptor to endocrine ablation in cancer of the breast. Surg Gynecol Obstet. 1974 Oct;139(4):525–528. [PubMed] [Google Scholar]
- Leung B. S., Sasaki G. H., Leung J. S. Estrogen-prolactin dependency in 7,12-dimethylbenz(a)anthracene-induced tumors. Cancer Res. 1975 Mar;35(3):621–627. [PubMed] [Google Scholar]
- Meites J. Relation of prolactin and estrogen to mammary tumorigenesis in the rat. J Natl Cancer Inst. 1972 Apr;48(4):1217–1224. [PubMed] [Google Scholar]
- Minton J. P., Dickey R. P. Levodopa test to predict response of carcinoma of the breast to surgical ablation of endocrine glands. Surg Gynecol Obstet. 1973 Jun;136(6):971–974. [PubMed] [Google Scholar]
- Minton J. P. Proceedings: The response of breast cancer patients with bone pain to L-dopa. Cancer. 1974 Feb;33(2):358–363. doi: 10.1002/1097-0142(197402)33:2<358::aid-cncr2820330209>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
- PEARSON O. H., RAY B. S. Results of hypophysectomy in the treatment of metastatic mammary carcinoma. Cancer. 1959 Jan-Feb;12(1):85–92. doi: 10.1002/1097-0142(195901/02)12:1<85::aid-cncr2820120114>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
- Sinha D., Cooper D., Dao T. L. The nature of estrogen and prolactin effect on mammary tumorigenesis. Cancer Res. 1973 Feb;33(2):411–414. [PubMed] [Google Scholar]
- Stoll B. A. Brain catecholamines and breast cancer: a hypothesis. Lancet. 1972 Feb 19;1(7747):431–431. doi: 10.1016/s0140-6736(72)90875-6. [DOI] [PubMed] [Google Scholar]